Marketing approval allows imminent commercialization of the Colovac device in key EU markets
PARIS, FRANCE AND TAMPA, FL / ACCESS Newswire / August 14, 2025 / SafeHeal®, a leading innovator in the field of colorectal cancer surgery, today announced that it has been granted European Union marketing approval for its Colovac device under the new Medical Device Regulation (EU MDR 2017/745, Medical Devices, Annex IX Chapter I). This significant milestone confirms the company’s compliance with the EU’s rigorous safety and performance standards, enabling commercial distribution of Colovac across the European Union. Colovac is intended as an alternative to temporary diverting ostomy for patients undergoing colorectal cancer resection.1,2
“This is a pivotal achievement for our company and a testament to the dedication of our regulatory, clinical, and engineering teams,” said Chris Richardson, President and Chief Executive Officer of SafeHeal. “We are now ready to bring the clinical and economic benefits of Colovac to healthcare providers and patients throughout Europe.”
The Colovac endoluminal bypass system is a less-invasive alternative to temporary diverting ostomy, the current standard of care for patients undergoing colorectal resection. Diverting ostomy is applied prophylactically to most patients today undergoing a low anterior resection (LAR) and anastomosis. The ostomy temporarily diverts the stool away from the healing anastomosis to the outside of the body and into an ostomy bag. In most cases, the ostomy is needed only until the anastomosis has healed, and then it can be reversed, typically after 2-6 months. The eventual reversal of the ostomy requires another operation, with a second hospital stay, recovery period and associated complications. In some cases, the ostomy may not be reversed and becomes permanent. In addition to the potential surgical complications associated with ostomy procedures, patients may experience an impact to their quality of life due to social isolation, reduced physical activity and/or intimacy.
Colovac is an alternative to diverting ostomy, designed to eliminate the need for a temporary stoma in most patients. It aims to improve patient recovery and quality of life by eliminating stoma related complications including permanent stoma and eliminating the physical and emotional burden associated with stoma management and care.
“Navigating the MDR process is no small feat for any company, and gaining approval affirms the strength of our technology and the robust data supporting it. After conducting a thorough review of the data supporting the performance and safety of the device and SafeHeal’s quality management system, the EU Medical Device regulators wasted no time in recognizing the obvious clinical benefits Colovac provides to colorectal cancer patients,” said Richardson.
Colovac has been successfully studied in the U.S., Europe, and Asia and the U.S. Food and Drug Administration (FDA) has already granted the product Breakthrough Device Designation. Breakthrough Device designation is granted to novel products and allows FDA to expedite the review of innovative technologies that can improve the lives of people with life-threatening or irreversibly debilitating diseases or conditions.
–
1 Intended Purpose: The Colovac Anastomosis Protection Device is intended for use in patients requiring low anterior rectal anastomoses to limit stoma creation to only those patients requiring more time for anastomosis healing when the device is removed, allowing patients with a healed anastomosis to avoid stoma creation.
2 Indication for Use: The SafeHeal Colovac Device is indicated for use following open, laparoscopic, or robotic-assisted laparoscopic colorectal surgery in patients indicated for diverting ostomy.
###
ABOUT SAFEHEAL®
SafeHeal SAS, headquartered in Paris, France, and its wholly owned U.S. subsidiary, SafeHeal Inc., is a medical device company developing Colovac, a device intended as an alternative to diverting ostomy in patients undergoing colorectal surgery. Colovac is a flexible endoluminal bypass sheath designed to reduce the contact of fecal content at the anastomotic site following colorectal surgery. The device is placed endoluminally and is fully reversible. The device remains in place for approximately 10 days, until the body’s natural healing and tissue repair processes are complete, after which it is removed during an endoscopic procedure without the need for a second surgical intervention. This enables patients to resume their normal life without the stigma and complications associated with an ostomy procedure. In the U.S., Colovac is limited by Federal law to investigational use and not currently available for sale. For more information, please visit www.safeheal.com.
MEDIA CONTACTS
USA
Scott DePierro
Vice President U.S. Operations and Global Business Development, SafeHeal
203-444-0279
sdepierro@safeheal.com
www.safeheal.com
Europe:
Karl-Heinz Blohm
Vice President, International, SafeHeal
+33 (0) 6 5181 7895
kblohm@safeheal.com
www.safeheal.com
SOURCE: SafeHeal
View the original press release on ACCESS Newswire
The post SafeHeal(R) Receives European Marketing Approval Under MDR for Colovac(R) Anastomosis Protection Technology appeared first on DA80 Hub.
